CN111297932A - Joint maintenance composite tablet for pets and preparation method thereof - Google Patents
Joint maintenance composite tablet for pets and preparation method thereof Download PDFInfo
- Publication number
- CN111297932A CN111297932A CN201911391476.1A CN201911391476A CN111297932A CN 111297932 A CN111297932 A CN 111297932A CN 201911391476 A CN201911391476 A CN 201911391476A CN 111297932 A CN111297932 A CN 111297932A
- Authority
- CN
- China
- Prior art keywords
- glucosamine
- sulfate
- pets
- vitamin
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Medical Informatics (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Fodder In General (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a joint maintenance composite tablet for pets and a preparation method thereof, belonging to the field of pet foods. The compound tablet of the invention contains active ingredients and auxiliary materials, and the active ingredients comprise: olibanum extract, and optionally glucosamine, chondroitin sulfate, vitamin D3, calcium hydrogen phosphate, copper sulfate, and manganese sulfate; the adjuvants include microcrystalline cellulose, carboxymethyl starch sodium, silicon dioxide, magnesium stearate, polyvinylpyrrolidone, and phagostimulant. The preparation method mainly comprises the steps of granulating, finishing, mixing and tabletting. The invention has good prevention and treatment effects on joint diseases of pets, and has good food calling effect.
Description
Technical Field
The invention belongs to the field of pet health care products, and particularly relates to a joint maintenance composite tablet for pets and a preparation method thereof.
Background
With the development of social economy and the acceleration of urbanization process, the problems of independence, individuation and population aging of urban residents are increasingly prominent, and the leisure, consumption and emotional bailing modes of residents are also in diversified development. Pet feeding has become a new bright spot for urban population consumption, and the pet industry has become an integral part of the urban economy. The number of domestic pets has increased dramatically, and the topics of pet fashion, pet supplies, pet hospitals, pet beauty, and pet beauty … …, which concern pets, have become more and more extensive, and the economy surrounding the pet industry has become more and more popular with people, and this field has therefore become a new pioneer "panning land".
According to the current domestic statistics, Chinese pet breeding mainly comprises dogs and cats, wherein the pet dogs have 85% of market share. Statistically about 20% of dogs over age 1 have varying degrees of arthritis and are often clinically overlooked. Especially some large dogs, such as labrador, rowiner, german shepherd, etc. Osteoarthritis can occur in virtually all ages and breeds of dogs, and in all joints.
Therefore, it is necessary to provide a health product for pets, which is convenient for dogs to swallow and can effectively prevent joint diseases.
Disclosure of Invention
The invention aims to provide a processing technology of a bimetal rechecking striking plate of a fan coal mill, and solves the technical problems.
In order to achieve the technical purpose and achieve the technical requirements, the invention adopts the technical scheme that: a joint maintenance composite tablet for pets, characterized in that: comprises active ingredients and auxiliary materials, wherein the active ingredients comprise glucosamine, chondroitin sulfate, frankincense extract, vitamin D3, calcium hydrophosphate, copper sulfate and manganese sulfate; the auxiliary materials comprise microcrystalline cellulose, carboxymethyl starch sodium, silicon dioxide, magnesium stearate, polyvinylpyrrolidone and a phagostimulant.
Further: the weight percentages of the components are as follows: glucosamine: 20-50%, chondroitin sulfate: 5-30%, frankincense extract: 1-10%, vitamin D3: 0.01-5%, copper sulfate: 0.01-5%, manganese sulfate: 0.01-5%, calcium hydrogen phosphate: 10-50%, microcrystalline cellulose: 1-20%, carboxymethyl starch sodium: 1-10%, silica: 1-10%, magnesium stearate: 0.01-5%, polyvinylpyrrolidone: 0.01-5%, phagostimulant: 5 to 30 percent.
Further: the glucosamine is glucosamine sulfate or hydrochloride or phosphate or a mixture thereof.
A preparation method of a joint maintenance compound preparation for pets comprises the following steps: the method comprises the following steps:
1) and (3) granulating: the preparation method comprises the steps of crushing and sieving glucosamine by 60-120 meshes, putting the glucosamine and chondroitin sulfate into a wet granulator, stirring for 1-10 minutes, adding a prepared 1-25% polyvinylpyrrolidone aqueous solution, granulating for 5-15 minutes, and then carrying out fluidized bed boiling drying.
2) Straightening: sieving the product obtained in the step 1) to obtain a sieve with 10-60 meshes;
3) mixing: putting the product obtained in the step 2) and the frankincense extract, the vitamin D3, the calcium hydrophosphate, the copper sulfate, the manganese sulfate, the microcrystalline cellulose, the sodium carboxymethyl starch, the silicon dioxide, the magnesium stearate and the phagostimulant in the formula into a mixing tank, and fully mixing for 20-40 minutes;
4) tabletting: tabletting the product obtained in the step 3) by a tabletting machine, and controlling the hardness to be 40-200N.
The invention has the following beneficial effects:
the invention takes glucosamine, chondroitin sulfate, frankincense extract, vitamin D3, calcium hydrogen phosphate, copper sulfate and manganese sulfate as active ingredients, has good prevention and treatment effects on joint diseases of pets, and the tablet prepared by the method has good food calling effect, optimal proportion of the dosage of raw materials and various auxiliary materials, strong product stability and high absorption and utilization rate.
The functions of the raw materials are as follows:
glucosamine is an important nutrient for the formation of chondrocytes, and is a natural tissue component of healthy articular cartilage. As pets age, the deficiency of glucosamine in the pet body becomes more severe, and articular cartilage is continually degraded and worn. A number of medical studies in the united states, europe and japan have shown that: glucosamine can improve inflammation symptoms and relieve joint pain, stiffness and swelling by stimulating chondrocytes to synthesize proteoglycan and collagen fibers, generating cartilage matrix, repairing damaged cartilage, and stimulating the generation of new cartilage. In addition, the glucosamine can promote joint synovial fluid generation, prevent friction and pain of bone joints, prevent joint aging, enable joints to move freely, restore joint gaps to be normal through repairing articular cartilage, and completely restore joint functions.
Chondroitin sulfate is a main representative of rich viscous substances proved by the current medicine, and the main application route in medicine is that the chondroitin sulfate is used as a medicine for treating joint diseases, is matched with glucosamine, has the effects of relieving pain and promoting cartilage regeneration, and can radically improve the joint problems. Chondroitin sulfate extracted from marine organisms can effectively supplement cartilage element proteoglycan, absorb and maintain water of cartilage, lubricate joints, thicken cartilage, increase the amount of synovial fluid in joints, remove inflammatory substances in joint cavities, repair joint cartilage, relieve joint pain and swelling and stiffness, and is called as 'joint cartilage gold' and 'joint liquid magnetite'.
More and more researches prove that the combination effect of the glucosamine and the chondroitin sulfate is better. The two are closely linked, supplement each other and are absorbed synergistically, and the medicine has the effect of 1+1>2 when treating osteoarthropathy.
The application history of frankincense is long, and the frankincense is a classic representative medicine for treating rheumatic joint diseases by traditional Chinese medicines at present. Modern pharmacological studies show that: the boswellic acid compounds have unique anti-inflammatory mechanism and are expected to become the first choice medicine for treating the rheumatoid arthritis. According to records in Ben Cao gang mu, Ru Xiang has the effects of alleviating pain, subduing swelling and promoting granulation. The frankincense extract can improve blood flow at joints and repair vascular atrophy caused by spasm, can be used for treating induced arthritis, and has good effect and no side effect.
Vitamin D3 is a fat-soluble vitamin, and can participate in the metabolism of calcium and phosphorus, promote absorption, and play an important role in bone formation. Vitamin D3 has the following physiological functions of 1, improving the absorption of calcium and phosphorus by the body and leading the levels of plasma calcium and plasma phosphorus to reach saturation. 2. Promoting growth and skeleton calcification, and promoting tooth health; 3. increased phosphorus absorption through the intestinal wall and increased phosphorus reabsorption through the renal tubules; 4. maintaining normal levels of citrate in the blood; 5. Preventing amino acid loss through the kidney.
Copper plays an important catalytic role in the hemopoiesis of dogs and plays an important role in promoting the bone health, and the dogs lack copper and can present deformity due to abnormal bone development and be easy to fracture.
Manganese is a mineral substance which can participate in the production of chondroitin sulfate in bones in dog bodies, and promotes healthy growth of the bones. When dogs lack manganese in vivo, the dogs can suffer from osteoporosis and the normal development of bones is influenced. This is because the bone contains osteoblasts and osteoclasts, which are opposite in physiological functions and supplement each other to maintain the metabolism of the bone. However, when the body is deficient in manganese, osteoclast activity is enhanced, osteoblast activity is inhibited, and growth rate is reduced, resulting in osteogenesis disorder. The homeostasis originally established in the body is disrupted and, over time, the bone mass becomes loose.
Detailed Description
Example 1
The total weight of the raw materials is 1000 g. Wherein, glucosamine: 200g, chondroitin sulfate: 60g, frankincense extract: 11g, vitamin D3: 5g, copper sulfate: 5g, manganese sulfate: 5g, calcium hydrogen phosphate: 254g, microcrystalline cellulose: 60g, sodium starch glycolate: 50g, silica: 50g, magnesium stearate: 30g, polyvinylpyrrolidone: 20g, phagostimulant: 250 g.
The preparation process comprises the following steps:
1) and (3) granulating: the glucosamine powder is crushed and sieved by a 100-mesh sieve, the glucosamine and the chondroitin sulfate are put into a wet granulator and stirred for 5 minutes, a prepared 10% polyvinylpyrrolidone water solution is added, granulation is carried out for 10 minutes, and fluidized bed boiling drying is carried out.
2) Straightening: sieving the product obtained in the step 1) to obtain a sieve with 20 meshes;
3) mixing: putting the product obtained in the step 2) and the frankincense extract, the vitamin D3, the calcium hydrophosphate, the copper sulfate, the manganese sulfate, the microcrystalline cellulose, the sodium carboxymethyl starch, the silicon dioxide, the magnesium stearate and the phagostimulant in the formula into a mixing tank, and fully mixing for 30 minutes;
4) tabletting: tabletting the product obtained in the step 3) by a tabletting machine, and controlling the hardness to be 60N.
Example 2
The total weight of the raw materials is 1000 g. Wherein, glucosamine: 373g, chondroitin sulfate: 220g, frankincense extract: 50g, vitamin D3: 1g, copper sulfate: 1g, manganese sulfate: 1g, calcium hydrogen phosphate: 124g, microcrystalline cellulose: 120g, sodium carboxymethyl starch: 20g, silica: 15g, magnesium stearate: 5g, polyvinylpyrrolidone: 10g, phagostimulant: 60 g.
The preparation process is the same as in example 1.
Example 3
The total weight of the raw materials is 1000 g. Wherein, glucosamine: 295g, chondroitin sulfate: 158g, boswellia extract: 34g, vitamin D3: 3g, copper sulfate: 3g, manganese sulfate: 3g, calcium hydrogen phosphate: 200g, microcrystalline cellulose: 98g, sodium starch glycolate: 35g, silica: 25g, magnesium stearate: 25g, polyvinylpyrrolidone: 15g, phagostimulant: 106 g.
The preparation process is the same as in example 1.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that it is obvious to those skilled in the art that various modifications and improvements can be made without departing from the principle of the present invention, and these modifications and improvements should also be considered as the protection scope of the present invention.
Claims (4)
1. A joint maintenance composite tablet for pets, characterized in that: comprises active ingredients and auxiliary materials, wherein the active ingredients comprise glucosamine, chondroitin sulfate, frankincense extract, vitamin D3, calcium hydrophosphate, copper sulfate and manganese sulfate; the auxiliary materials comprise microcrystalline cellulose, carboxymethyl starch sodium, silicon dioxide, magnesium stearate, polyvinylpyrrolidone and a phagostimulant.
2. The joint maintenance composite tablet for pets according to claim 1, wherein: the weight percentages of the components are as follows: glucosamine: 20-50%, chondroitin sulfate: 5-30%, frankincense extract: 1-10%, vitamin D3: 0.01-5%, copper sulfate: 0.01-5%, manganese sulfate: 0.01-5%, calcium hydrogen phosphate: 10-50%, microcrystalline cellulose: 1-20%, carboxymethyl starch sodium: 1-10%, silica: 1-10%, magnesium stearate: 0.01-5%, polyvinylpyrrolidone: 0.01-5%, phagostimulant: 5 to 30 percent.
3. The joint maintenance composite tablet for pets according to claim 1, wherein: the glucosamine is glucosamine sulfate or hydrochloride or phosphate or a mixture thereof.
4. A preparation method of a joint maintenance compound preparation for pets comprises the following steps: the method comprises the following steps:
and (3) granulating: crushing and sieving glucosamine by 60-120 meshes, putting the glucosamine and chondroitin sulfate into a wet granulator, stirring for 1-10 minutes, adding a prepared 1-25% polyvinylpyrrolidone aqueous solution, granulating for 5-15 minutes, and then carrying out fluidized bed boiling drying;
straightening: sieving the product obtained in the step 1) to obtain a sieve with 10-60 meshes;
mixing: putting the product obtained in the step 2) and the frankincense extract, the vitamin D3, the calcium hydrophosphate, the copper sulfate, the manganese sulfate, the microcrystalline cellulose, the sodium carboxymethyl starch, the silicon dioxide, the magnesium stearate and the phagostimulant in the formula into a mixing tank, and fully mixing for 20-40 minutes;
tabletting: tabletting the product obtained in the step 3) by a tabletting machine, and controlling the hardness to be 40-200N.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911391476.1A CN111297932A (en) | 2019-12-30 | 2019-12-30 | Joint maintenance composite tablet for pets and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911391476.1A CN111297932A (en) | 2019-12-30 | 2019-12-30 | Joint maintenance composite tablet for pets and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111297932A true CN111297932A (en) | 2020-06-19 |
Family
ID=71154524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911391476.1A Withdrawn CN111297932A (en) | 2019-12-30 | 2019-12-30 | Joint maintenance composite tablet for pets and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111297932A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114343184A (en) * | 2020-12-29 | 2022-04-15 | 江苏艾兰得营养品有限公司 | Preparation method of ammonia sugar composite functional tablet |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101653451A (en) * | 2009-09-04 | 2010-02-24 | 江苏江山制药有限公司 | Health product for keeping joint health and increasing bone density and preparation method thereof |
| CN104621432A (en) * | 2013-11-12 | 2015-05-20 | 江苏艾兰得营养品有限公司 | Glucosamine composite tablets and preparation method thereof |
| CN109984269A (en) * | 2017-12-29 | 2019-07-09 | 瑞普（天津）生物药业有限公司 | It is a kind of with the pet nutrition cream and preparation method of replenishing the calcium and keep articulation health |
-
2019
- 2019-12-30 CN CN201911391476.1A patent/CN111297932A/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101653451A (en) * | 2009-09-04 | 2010-02-24 | 江苏江山制药有限公司 | Health product for keeping joint health and increasing bone density and preparation method thereof |
| CN104621432A (en) * | 2013-11-12 | 2015-05-20 | 江苏艾兰得营养品有限公司 | Glucosamine composite tablets and preparation method thereof |
| CN109984269A (en) * | 2017-12-29 | 2019-07-09 | 瑞普（天津）生物药业有限公司 | It is a kind of with the pet nutrition cream and preparation method of replenishing the calcium and keep articulation health |
Non-Patent Citations (1)
| Title |
|---|
| 李凯年等: "犬骨关节炎的诊断与治疗", 《中国动物保健》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114343184A (en) * | 2020-12-29 | 2022-04-15 | 江苏艾兰得营养品有限公司 | Preparation method of ammonia sugar composite functional tablet |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2971579B2 (en) | Amino sugar and glycosaminoglycan compositions for the treatment and recovery of connective tissue | |
| CN1903220B (en) | Health-care food with function of improving skeletal density and its prepn. method | |
| US6492349B1 (en) | Aminosugar and glycosaminoglycan composition for the treatment and repair of connective tissue | |
| CN101559218B (en) | Composition with function of increasing bone density | |
| KR101594137B1 (en) | composition for health functional food improving joint health | |
| CN101537050B (en) | Health product capable of enhancing bone density and immune function, and preparation method and applications thereof | |
| CA2840895A1 (en) | Composition for maintaining bone health and for treating osteoarthritis and osteoarthrosis of the joints | |
| CN101720928A (en) | Combination for preventing and curing degenerative disease of bone and joint | |
| CN107375221A (en) | One kind contains farnoquinone calcium tablet and preparation method thereof | |
| CA1314233C (en) | Calcium supplements | |
| KR20100107468A (en) | Formulas comprising calcium, magnesium, zinc, and vitamine d3 for the prevention and amelioration of osteoporosis | |
| EP0304986B1 (en) | The use of certain calcium-citrate-malate for the manufacture of a medicament for the treatment of osteoporosis | |
| CN111297932A (en) | Joint maintenance composite tablet for pets and preparation method thereof | |
| CN103251065A (en) | Domesticated sika deer bone meal as well as preparation method thereof and sika deer bone chewable tablet prepared from bone meal | |
| EP1408988B1 (en) | Compositions of orally administered nutritional supplements to repair articular cartilage | |
| CN1739556A (en) | Dietotherapeutic nutrient for preventing and treating secondary gout and its prepn process | |
| CN104523804B (en) | A kind of capsule for increasing bone density and preparation method thereof | |
| CN101692902A (en) | Food compositions for lowering and releasing uric acid and preventing gout | |
| CN103494201B (en) | Osteoarticular disease care product of L-ascorbyl dipalmitate | |
| CN109674799B (en) | Application of betulinic acid in body lead elimination and preparation of lead elimination food, health-care product and medicine | |
| WO2021100837A1 (en) | Composition for preventing or reducing hyperuricemia, and method for producing same | |
| CN1739551A (en) | Dietotherapeutic nutrient for treating primary urate calculi and gout and its prepn process | |
| CN1739574A (en) | Dietotherapeutic nutrient for preventing and treating gout and its prepn process | |
| JP2007254403A (en) | Cartilage formation promoter containing galacturonic acid as active ingredient | |
| KR20060023503A (en) | A composition for curing and prevention of heart and vascular disease, acidify of blood |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20200619 |
|
| WW01 | Invention patent application withdrawn after publication |